New Delhi, July 21 (H.S.): Anthem Biosciences’ shares had a strong debut on the stock market, with an IPO price of ₹570. They opened at ₹723.10 on the BSE and ₹723.05 on the NSE, resulting in a listing gain of around 26%. After initial trading, prices rose to ₹746.70 and ₹747, respectively, but a selling trend led to a slight decline. The shares closed at ₹730.35, yielding IPO investors a profit of ₹160.35, approximately 28.13%. The IPO, amounting to ₹3,395.79 crores, was open for subscription from July 14 to 16 and was oversubscribed 67.42 times overall.

The Qualified Institutional Buyers’ portion was subscribed 192.80 times, Non-Institutional Investors’ portion 44.70 times, and retail investors’ portion 5.98 times, with employee’s portion at 6.99 times. No new shares were issued; instead, 5,95,75,319 shares with a face value of ₹2 were sold. The company’s financial health remains strong, reporting a net profit increase from ₹385.19 crores in FY 2022-23 to ₹451.26 crores in FY 2024-25, with revenue growing at a CAGR of over 30%.

Hindusthan Samachar / Jun Sarkar